Status:
UNKNOWN
Evaluation of the PhageTech Virus BioResistor
Lead Sponsor:
PhageTech, Inc.
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Brief Summary
To evaluate the effectiveness of the PhageTech Virus BioResistor to detect bladder cancer biomarkers.
Detailed Description
This study will sample urine provided by bladder cancer patients as part of their normal routine surveillance screening. No additional effort will be required from the patients and only modest additio...
Eligibility Criteria
Inclusion
- Male and female patients ≥ 18 years
- Previous bladder cancer diagnosis; any stage and histological type, undergoing cystoscopy
- Patients with suspected bladder tumor undergoing surveillance cystoscopy
- Patients must provide written Informed Consent.
Exclusion
- Patients unable or unwilling to sign the informed consent
- Age \< 18 years
- Known HIV/HCV/HBV (information from clinical history).
Key Trial Info
Start Date :
February 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 11 2021
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04756284
Start Date
February 8 2021
End Date
November 11 2021
Last Update
February 16 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Providence Saint John's Health Center and the Saint John's Cancer Institute
Santa Monica, California, United States, 90404